Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Banner image

Press Release

Fish & Richardson Named IP Litigation Powerhouse in BTI Survey of In-House Counsel

October 18, 2018

Press Release

Fish & Richardson Named IP Litigation Powerhouse in BTI Survey of In-House Counsel

October 18, 2018

Back to News Listing

Fish & Richardson has been named one of seven elite “Litigation Powerhouses” in IP Litigation in the BTI Litigation Outlook 2019 survey, based on a survey of over 350 top legal decision makers. In-house counsel turn to Litigation Powerhouse firms “for their most pressing litigation needs” because they deliver “the best results, the best expertise, the best value, and the best client service.”

Fish’s global IP litigation practice has a proven and extensive track record of successfully handling high-tech, high-stakes matters. In addition to world-class trial lawyers, Fish brings an unrivaled level of technical expertise to every case, with 423 attorneys and technology specialists with undergraduate and graduate degrees in science and technology, 87 of whom have Ph.D.’s.

“No firm in the world can match Fish’s winning track record in intellectual property trials. We are in demand because of our outstanding trial skills. We handle more cases in district court, at the ITC and at the Court of Appeals for the Federal Circuit than any other firm, and clients trust us with their most important matters,” said Kurt Glitzenstein, Practice Group Leader for Fish’s Litigation Group. “Fish’s trial lawyers are in court nearly every day. We know how to present the facts and the law in ways that are both clear and compelling to judges and to juries, and that is why we outperform other firms in high-stakes patent infringement actions.”

Fish’s big wins over the past year include two victories for client Gilead Sciences protecting their blockbuster drugs Sovaldi® and Harvoni®, which cure hepatitis C. In Idenix Pharmaceuticals LLC et al. v. Gilead Sciences, Inc., Fish reversed a $2.5 billion willful infringement jury verdict against Gilead after winning a rare motion for judgment as a matter of law. In Gilead Sciences, Inc. v. Merck & Co. Inc. et al., Fish’s all-women oral argument team won a unanimous Federal Circuit opinion that affirmed Fish’s successful post-trial vacatur of a $200 million jury verdict against Gilead. Fish also won several cases for long-time client Microsoft, among many others.